Sumitovant Biopharma And Sumitomo Pharma Announce Offer To Acquire Outstanding Shares Of Myovant Sciences
Acquiring Company
Sumitovant Biopharma Ltd
Acquired Company
Tramo Group
ChiassoBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaBiotechnologyHealth CarePharmaceuticalDescription
Sumitovant Biopharma Ltd. ("Sumitovant"), in conjunction with parent company Sumitomo Pharma Co., Ltd. ("Sumitomo Pharma"), announced today it has submitted a non-binding proposal (the "Proposal") to the Audit Committee of the Board of Directors (the "Audit Committee") of Myovant Sciences Ltd. ("Myovant") offering to acquire all outstanding shares of Myovant not already owned by Sumitovant for $22.75 per share in cash. The proposed transaction, if completed, would result in Myovant being delisted from the New York Stock Exchange (NYSE).
Quick answer
Sumitovant Biopharma Ltd and Sumitomo Pharma Ltd are acquiring Tramo Group, announced October 2, 2022.
- How much did Sumitovant Biopharma Ltd pay for Tramo Group?
- The deal value was not disclosed.
- What does Sumitovant Biopharma Ltd do?
- Sumitovant is a technology-driven biopharmaceutical company accelerating development and commercialization of new potential therapies for patients with rare conditions and other diseases.
- Where are Sumitovant Biopharma Ltd and Tramo Group based?
- Tramo Group is based in Chiasso, Switzerland.
Source: Fundz verified event record.
Other recent acquisitions in Therapeutics and Pharmaceutical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Atossa Therapeutics, Inc. To Acquire Stake In Privately Held Dynamic Cell Therapies As Part Of Overall Car-T Strategy (November 1, 2022)
- Pfizer Completes Acquisition Of Global Blood Therapeutics (October 5, 2022)
- Pfizer Completes Acquisition Of Biohaven Pharmaceuticals (October 3, 2022)
- Amgen Successfully Completes Acquisition Of Chemocentryx (October 20, 2022)
- Lilly To Acquire Akouos To Discover And Develop Treatments For Hearing Loss (October 18, 2022)
- Incyte Announces Agreement To Acquire Medicxi-Backed Villaris Therapeutics And Auremolimab (Vm6), An Anti-Il-15Rβ Monoclonal Antibody (October 3, 2022)
Who to call at Sumitovant Biopharma Ltd, and when
When Sumitovant Biopharma Ltd changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Sumitovant Biopharma Ltd raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Sumitovant Biopharma Ltd, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Sumitovant Biopharma Ltd. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Sumitovant Biopharma Ltd makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Tramo Group?
Tramo Group was acquired by Sumitovant Biopharma Ltd. The deal was reported on October 2, 2022. Sumitovant is a technology-driven biopharmaceutical company accelerating development and commercialization of new potential therapies for patients with rare conditions and other diseases. Sumitovant Biopharma Ltd is privately held and operates in Biotechnology.
When did Sumitovant Biopharma Ltd acquire Tramo Group?
Sumitovant Biopharma Ltd's acquisition of Tramo Group was reported on October 2, 2022. Sumitovant Biopharma Ltd. ("Sumitovant"), in conjunction with parent company Sumitomo Pharma Co., Ltd. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Tramo Group do?
For more than 30 years, Tramo Group has specialized in logistics and transport of high-end furniture and furnishing components and it is a partner of the most respected names in the design world. Contact: info@tramo.it It is privately held, and is based in Chiasso.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.